Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Gilead Sciences, Inc shares valued at $1,139,370 were sold by O’Day Daniel Patrick on Jul 28 ’25. At $113.94 per share, O’Day Daniel Patrick sold 10,000 shares. The insider’s holdings dropped to 605,725 shares worth approximately $69.51 million following the completion of this transaction.
Also, DANIEL ODAY purchased 10,000 shares, netting a total of over 1,139,369 in proceeds.
Before that, Mercier Johanna had sold 3,000 shares from its account. In a trade valued at $333,090, the Chief Commercial Officer traded Gilead Sciences, Inc shares for $111.03 each. Upon closing the transaction, the insider’s holdings decreased to 3,000 shares, worth approximately $13.45 million.
As published in a research note from Needham on July 25, 2025, Gilead Sciences, Inc [GILD] has been rated up from a Hold to a Buy and the price target has been revised to $133. As of March 04, 2025, Oppenheimer has reiterated its “an Outperform” rating for GILD. Earlier on February 18, 2025, Deutsche Bank upgraded its rating. Their new recommendation was “a Buy” for GILD stock which previously was a “a Hold”.
Analyzing GILD Stock Performance
On last trading session,, Gilead Sciences, Inc [NASDAQ: GILD] rose 0.46% to $114.76. The stock’s lowest price that day was $113.61, but it reached a high of $115.74 in the same session. During the last five days, there has been a surge of approximately 1.06%. Over the course of the year, Gilead Sciences, Inc shares have jumped approximately 49.02%.
Support And Resistance Levels for Gilead Sciences, Inc (GILD)
RSI (Relative Strength Index) is 58.24 on the 14-day chart, showing neutral technical sentiment.
Is Gilead Sciences, Inc subject to short interest?
Stocks of Gilead Sciences, Inc saw a sharp steep in short interest on 2025-07-15 dropping by -0.45 million shares to 22.54 million. Data from Yahoo Finance shows that the short interest on 2025-06-13 was 22.99 million shares. A decline of -2.01% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 2.8 of the overall float, the days-to-cover ratio (short ratio) decline to 2.8.
Which companies own the most shares of Gilead Sciences, Inc (GILD)?
In terms of Gilead Sciences, Inc share price expectations, FactSet research, analysts set an average price target of 126 in the next 12 months, up nearly 10.3% from the previous closing price of $114.23. Analysts anticipate Gilead Sciences, Inc stock to reach 135 by 2025, with the lowest price target being 114. In spite of this, 17 analysts ranked Gilead Sciences, Inc stock as Buy at the end of 2025. On February 13, 2025, DZ Bank assigned a price target of “a Buy” to the stock and upgraded coverage with a $108.
